Clover Health Investments, Corp. · NASDAQ:CLOV
Clover Health Investments — J.P. Morgan Healthcare Conference 2024
22 slides from Clover Health Investments's conference presentation, Jan 10, 2024
Slide 1: Clover Health J.P. Morgan Healthcare Conference January 2024
Clover Health J.P. Morgan Healthcare Conference January 2024
Slide 2: Disclaimer
2 Disclaimer This presentation and the accompanying oral presentation include forward-looking statements, including statements regarding future events including, without limitation, Clover Health Investments, Corp.’s (“Clover Health,” “we,” “our,” or “us”), expectations regarding positive Adjusted E
Slide 3: Our Vision
3 Our Vision Empowering Physicians to Identify and Manage Chronic Diseases Earlier
Slide 4: 2023 in Review
Clover Health 2023 in Review
Slide 5: Strong Financial Performance in Medicare Advantage
5 (1) For comparison purposes, 2023 Outlook is based on guidance provided in the Company’s November 6, 2023 earnings press release, which was most recently reiterated by the Company in its December 21, 2023 press release, and has not been updated since that date. Insurance Revenue and Insurance Gros
Slide 6: Driven By an Asset-Light Care Management Platform
…Driven By an Asset-Light Care Management Platform 6 Strong Financial Performance in Medicare Advantage (1) For comparison purposes, 2023 Outlook is based on guidance provided in the Company’s November 6, 2023 earnings press release, which was most recently reiterated by the Company in its December
Slide 7: Strong 2023 Momentum Continues into 2024
7 Continue to drive toward long-term growth levers and expanding our offerings Targeting full-year 2024 positive Adjusted EBITDA Prudently manage strong liquidity position to achieve path to profitability Improve Medicare Advantage fundamentals while reducing operational spend 1 4 2 3 Strong 2023 Mo
Slide 8: The Clover Health Story
Clover Health The Clover Health Story
Slide 9: How is Clover Health Different?
Solely focused on Medicare, serving a population with chronic conditions that can be proactively managed Technology R&D entirely focused on physician enablement technology, bringing together the power of AI + data to real-world care Home-based, “officeless” clinical practice delivers in-person + vir
Slide 10: Wide Network Approach Positions Clover to Service the ~$900B Medicare Market
10 Wide Network Approach Positions Clover to Service the ~$900B Medicare Market Source: Congressional Budget Office (CBO), U.S. Census Bureau - Population Estimates and Projections, Association of American Medical Colleges (AAMC), CMS, Kaiser Family Foundation. Note: Senior population and MA Enrollm
Slide 11: An Asset-Light Care Management Platform Enables a Wide Network Approach
In-Home Primary Care. Fully accountable, high-touch primary care & supportive care program for members most at risk Care Coordination. Annual in-home assessments and post-discharge visits coordinate care for a rising risk population Interdisciplinary care. Diverse care team, powered by CA to deliver
Slide 12: Impact of Clover Assistant and Clover Home Care
Thousands of clinicians currently using CA generated insights to care for Tens of Thousands of patients Correlated with Changes to the Timeline of Care as shown in Clover’s three research papers on better care for Chronic Kidney Disease, Diabetes, and improved Medication Adherence(1) Impact of Clove
Slide 13: Clover Assistant: Creating the Software-Powered Physician
13 Clover Assistant: Creating the Software-Powered Physician
Slide 14: Earlier Diagnosis Leads to Earlier Treatment: Chronic Kidney Disease
14Note: Kidney Function measured via GFR (Glomerular Filtration Rate). (1) “Clover Assistant Use and Diagnosis and Progression of Chronic Kidney Disease” www.cloverhealth.com/clinicalcare/ckd Earlier Diagnosis Leads to Earlier Treatment Example: Chronic Kidney Disease ~1.5 years CA Patients Non-CA P
Slide 15: Earlier Diagnosis Leads to Earlier Treatment: Diabetes
15 Note: This slide reflects our examination of data from Clover Health members who had no previously recorded diagnosis of diabetes, were flagged by the ‘at-risk’ algorithm in Clover Assistant, and where the clinician had a visit informed by Clover Assistant data (2018 - 2022) and the clinician con
Slide 16: Earlier Diabetes Treatment Leads to
16 Earlier Diabetes Treatment Leads to: Note: This slide reflects our examination of data from Clover Health members who had no previously recorded diagnosis of diabetes, were flagged by the ‘at-risk’ algorithm in Clover Assistant, and where the clinician had a visit informed by Clover Assistant dat
Slide 17: Clover Assistant Correlated with Improved Medication Adherence
Medication fills increased by ~5% on the day of the Clover Assistant visit and remained ~3% higher 90 days post-visit among patients previously non-adherent to their medications for diabetes, high blood pressure, and high cholesterol(1) Days Since Visit 17 Note: Analyses examined data from Clover He
Slide 18: Looking Forward
Clover Health Looking Forward
Slide 19: Goals for 2024 and Beyond
Move to sustainable, profitable growth leveraging further improvements in our care management platform Profitable Growth Return to 3.5 Star Rating, with pathway to further upside at higher levels Improve Star Rating 19 Goals for 2024 and Beyond Targeting full-year 2024 positive Adjusted EBITDA as Cl
Slide 20: Q&A
Clover Health Q&A
Slide 21: Appendix
Appendix
Slide 22: About Non-GAAP Financial Measures
22 About Non-GAAP Financial Measures (1) In addition to U.S. Generally Accepted Accounting Principles (“GAAP”) financial measures, this presentation includes certain non-GAAP financial measures including Adjusted EBITDA. These non-GAAP financial measures are provided to enhance the reader’s understa
Clover Health Investments — J.P. Morgan Healthcare Conference 2024 on 6ix